Format
Items per page
Sort by

Send to:

Choose Destination

Links from Books

Items: 8

1.

Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications.

Fani M, Braun F, Waser B, Beetschen K, Cescato R, Erchegyi J, Rivier JE, Weber WA, Maecke HR, Reubi JC.

J Nucl Med. 2012 Sep;53(9):1481-9. doi: 10.2967/jnumed.112.102764. Epub 2012 Jul 31.

2.

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.

Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, Erchegyi J, Rivier J, Mäcke HR, Reubi JC.

Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16436-41. Epub 2006 Oct 20.

3.

Somatostatin receptor subtypes: basic pharmacology and tissue distribution.

Corleto VD, Nasoni S, Panzuto F, Cassetta S, Delle Fave G.

Dig Liver Dis. 2004 Feb;36 Suppl 1:S8-16. Review.

PMID:
15077906
4.

Opportunities in somatostatin research: biological, chemical and therapeutic aspects.

Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C.

Nat Rev Drug Discov. 2003 Dec;2(12):999-1017. Review. No abstract available. Erratum in: Nat Rev Drug Discov. 2005 Dec;4(12):975.

PMID:
14654798
5.

Somatostatin receptors.

Møller LN, Stidsen CE, Hartmann B, Holst JJ.

Biochim Biophys Acta. 2003 Sep 22;1616(1):1-84. Review.

6.

Somatostatin and somatostatin receptor physiology.

Barnett P.

Endocrine. 2003 Apr;20(3):255-64. Review.

PMID:
12721505
7.

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.

Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR.

Eur J Nucl Med. 2000 Mar;27(3):273-82.

PMID:
10774879
8.

In vivo and in vitro plasma disappearance and metabolism of somatostatin-28 and somatostatin-14 in the rat.

Patel YC, Wheatley T.

Endocrinology. 1983 Jan;112(1):220-5. No abstract available.

PMID:
6128222
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk